NAD+

The published human work is about tolerability rather than effect. A retrospective pilot compared intravenous NAD+ against nicotinamide riboside in a real-world setting and recorded clinician- and participant-reported adverse experiences including nausea, diarrhoea, muscle cramping, chest pain and dizziness. A randomised placebo-controlled pilot examined acute intravenous administration in healthy adults. Related work has examined raising the NAD+ metabolome by oral precursors in a randomised triple-blind crossover design, which is a different question from administering the coenzyme itself.

What is not established

Systematic safety and tolerability investigation, which the published work says plainly remains limited despite widespread use. There is no standardised dose, no labelled route and no approved product. The oral-precursor literature does not transfer: raising the metabolome with a precursor and infusing the coenzyme are not the same intervention, and the studies that exist do not establish that they produce the same thing.

What distinguishes NAD+

This is the compound where the regulator's published concern is about the GRADE of the material rather than the molecule. FDA has said it is aware of food-grade NAD+ from repackagers being used to make injectables, and that food-grade material is not suitable for sterile work because of microbial and endotoxin contamination risk. For a buyer that reframes the question entirely: with this compound, what the certificate says about grade, endotoxin and bioburden is the product, and the molecule is the easy part.

Sources

1. US FDA. FDA reminds compounders to use ingredients suitable for sterile compounding
2. US FDA. Bulk drug substances used in compounding
3. US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks
4. Intravenous infusion of nicotinamide adenine dinucleotide versus nicotinamide riboside: a retrospective tolerability pilot study in a real-world setting
5. A combination of nicotinamide and D-ribose is safe and effective to increase the NAD+ metabolome in healthy middle-aged adults: randomised, triple-blind, placebo-controlled crossover pilot

This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.